JAK inhibitors in chronic plaque psoriasis: What is known so far.

JAK inhibitors in chronic plaque psoriasis: What is known so far.
Drugs Today (Barc). 2020 Feb;56(2):151-163
Authors: Plachouri KM, Georgiou S
Abstract
Janus kinase (JAK) inhibitors are novel small molecules with a mechanism of action in multiple signaling pathways that allows their application in a broad spectrum of autoimmune and autoinflammatory diseases. As far as the field of dermatology is concerned, chronic plaque psoriasis is currently one of the most studied indications regarding the potential use of JAK inhibitors. The purpose of this review is to provide a summarized overview of the existing information on the efficacy and safety of JAK inhibitors in plaque psoriasis, with a focus on tofacitinib, ruxolitinib, baricitinib, peficitinib and filgotinib. Although the published data on the therapeutic benefit of these agents in the therapy of this chronic condition are promising, further prospective studies and real-life data are necessary in order to sufficiently evaluate their role as an adequate treatment option for psoriatic patients.
PMID: 32163530 [PubMed - in process]

Source: Drugs of Today - March 14, 2020 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research